Immunotherapy of Diffuse Gliomas: Biological Background, Current Status and Future Developments
Mayo Clinic · Radboud University Nijmegen · +1 more institution
Abstract
Despite aggressive multimodal treatment approaches, the prognosis for patients with diffuse gliomas remains disappointing. Glioma cells often extensively infiltrate in the surrounding brain parenchyma, a phenomenon that helps them to escape surgical removal, radiation exposure and chemotherapy. Moreover, conventional therapy is often associated with considerable local and systemic side effects. Therefore, the development of novel therapeutic approaches is essential to improve the outcome of these patients. Immunotherapy offers the opportunity to specifically target residual radio-and chemoresistant tumor cells without damaging healthy neighboring brain tissue. Significant progress has been made in recent years…
Citation impact
- FWCI
- 19.79
- Percentile
- 100%
- References
- 449
Authors
3- OMOliver M. GrauerCorresponding
Mayo Clinic, Radboud University Nijmegen, Radboud University Medical Center
- PWPieter Wesseling
- GJGosse J. Adema
Topics & keywords
- Immunotherapy
- Glioma
- Immunosuppression
- Medicine
- Immune system
- Radiation therapy
- Central nervous system
- Neuroimmunology
- Good health and well-being